Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents

Ann Oncol. 2012 Aug;23(8):1934-1936. doi: 10.1093/annonc/mds116. Epub 2012 Apr 17.

Authors

A Greystoke¹, M Ranson²

Affiliations

¹ Drug Development Unit, Christie NHS Trust, Manchester, UK. Electronic address: [email protected].
² Drug Development Unit, Christie NHS Trust, Manchester, UK.

PMID: 22510374
DOI: 10.1093/annonc/mds116

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Agents / adverse effects*
Female
Humans
Male
Molecular Targeted Therapy / adverse effects*
Neoplasms / drug therapy*

Substances

Antineoplastic Agents